Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: The EUELC cohort

Chiara Scoccianti, Aurélien Vesin, Ghislaine Martel, Magali Olivier, Elisabeth Brambilla, Jean François Timsit, Luca Tavecchio, Christian Brambilla, John K. Field, Pierre Hainaut, J. K. Field, C. Brambilla, Y. Martinet, E. Thunnissen, P. Snijders, G. Sozzi, A. Risch, S. Elborn, L. M. Montuenga, K. O'ByrneD. J. Harrison, J. Niklinski

Research output: Contribution to journalArticlepeer-review


Nonsmall cell lung cancer samples from the European Early Lung Cancer biobank were analysed to assess the prognostic significance of mutations in the TP53, KRAS and EGFR genes. The series included 11 never-smokers, 86 former smokers, 152 current smokers and one patient without informed smoking status. There were 110 squamous cell carcinomas (SCCs), 133 adenocarcinomas (ADCs) and seven large cell carcinomas or mixed histologies. Expression of p53 was analysed by immunohistochemistry. DNA was extracted from frozen tumour tissues. TP53 mutations were detected in 48.8% of cases and were more frequent among SCCs than ADCs (p

Original languageEnglish
Pages (from-to)177-184
Number of pages8
JournalEuropean Respiratory Journal
Issue number1
Publication statusPublished - Jul 1 2012


  • EGFR
  • KRAS
  • Mutations
  • Nonsmall cell lung cancer
  • Prognosis
  • TP53

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: The EUELC cohort'. Together they form a unique fingerprint.

Cite this